Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas

Clinical Cancer Research

Volumn 7, Issue 3, 2001, Pages 570-576

  Lakka, Sajani S ^a   Konduri, Santhi D ^a   Mohanam, Sanjeeva ^a   Rao, Jasti S ^a   Rao, Chilukuri N ^b   Kin, Yoshiaki ^b   Fuller, Gregory N ^c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Neurosurgery   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACENTA PROTEIN 5; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; NORTHERN BLOTTING; PRIORITY JOURNAL; TUMOR GROWTH; WESTERN BLOTTING;

ASTROCYTOMA; BLOTTING, NORTHERN; BLOTTING, WESTERN; BRAIN; BRAIN NEOPLASMS; COLLAGEN; DISEASE PROGRESSION; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GLIOMA; GLYCOPROTEINS; HUMANS; IN SITU HYBRIDIZATION; LAMININ; NEURONS; PROTEOGLYCANS; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0034895082     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Expression and localization of urokinase-type plasminogen activator in human astrocytoma in vivo
2. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody
3. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas
4. Plasminogen activators, tissue degradation, and cancer
5. Plasmin in pericellular proteolysis and cellular invasion
6. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor
7. Purification and characterization of placental protein-5
8. Partial characterization of matrix-associated serine protease inhibitors from human skin cells
9. Novel extracellular matrix-associated serine protease inhibitors from human skin cells
10. Partial characterization of novel serine protease inhibitors from human umbilical vein endothelial cells
11. r 33, 000, 31, 000, and 27, 000) are single-gene products with differential glycosylation: Cdna cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2
12. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibits (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate. Heparin accelerates the activity of TFPI-2/MSPI toward plasmin
13. Assignment of the human PP5/TFPI-2 gene to 7Q 22 by FISH and PCR-based human mapping panel analysis
14. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by matrix associated serine protease inhibitor, TFPI-2/33 kDa MSPI
15. Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to nitrocellulose sheets: Procedures and some applications
16. Single-step method of RNA isolation by acid guanidium thio cyanate-phenolchloroform extraction
17. r, 92, 000 type IV collagenase in human brain tumors
18. Overexpression and localization of cathepsin B during the progression of human gliomas
19. Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line
20. Purification and properties of extracellular matrix-degrading metalloproteinase overproduced by Rous sarcoma virus-transformed rat liver cell line, and its identification as transin
21. Comparison of extracellular matrix-degrading activities between 64-kDa and 90-kDa gelatinases purified in inhibitor-free forms from human Schwannoma cells
22. Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines
23. Identification of one-and-two-chain forms of trypsinogen 1 produced by a human gastric adenocarcinoma cell line
24. The urokinase-type plasminogen activator system in cancer metastasis: A review
25. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis
26. The plasminogen-activator (PA) system in neuroblastoma: Role of PA inhibitor-1 in metastasis
27. Expression and cellular localization of messenger RNA for plasminogen activator inhibits type 1 in human astrocytoma in vivo
28. The plasminogen-plasmin system in malignancy
29. Regulation of ProMMP-1 and ProMMP-3 activation of tissue factor pathway inhibitor-2/matrix associate serine protease inhibitor
30. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma
31. Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface bound reactants
32. Plasminogen activation by tPA on the surface of human melanoma cells in the presence of α-2 macroglobulin secretion
33. Metastatic behavior of human melanoma cells in nude mice correlates with urokinase-type plasminogen activator its type-1 inhibitor and urokinase mediated degradation
34. Binding and activation of plasminogen at the surface of human keratinocytes
35. Binding of protease nexin-1 to the fibroblast cell surface alters its target proteinase specificity
36. Identification of a novel serpin with tumor suppressing activity in human mammary epithelial cells
37. The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin
38. Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin
39. Maspin suppresses the invasive phenotype of human breast carcinoma
40. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor
41. Thrombosis and cancer
42. Tissue factor in cancer angiogenesis and metastasis
43. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization of in situ of clotting proteins and vascular endothelial growth factor in cancer
44. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII
45. Enhanced expression of urokinase receptor induced through the tissue factor VIIa pathway in human pancreatic cancer
46. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease
47. Expression of tissue factor by human melanoma cells promotes efficient hematogenous metastasis
48. The angiogenic effects of tissue factor on tumors and wounds
49. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis